Clinical trial
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
NCT00182754 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00182754 |
|---|---|
| Title | Octreotide in Treating Patients With Cancer-Related Malignant Ascites |
| Official title | An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LARDepot) for Symptomatic Ascites in Cancer Patients |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | octreotide acetate, placebo |
| Enrollment | 33 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | Mar 1, 2013 |
| First posted | Sep 16, 2005 |
| Last update posted | Apr 11, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: